References
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia38, 1–211 (2018).
- Bonafede M , SapraS , ShahN , TepperS , CappellK , DesaiP. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache58(5), 700–714 (2018).
- Burch RC , LoderS , LoderE , SmithermanTA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache55(1), 21–34 (2015).
- Kuruvilla DE , BilchikT. Preventing the progression of episodic migraine to chronic migraine with acute treatment optimization. Curr. Pain Headache Rep.26, 253–258 (2022).
- Starling AJ , DodickDW. Best practices for patients with chronic migraine: burden, diagnosis, and management in primary care. Mayo Clin. Proc.90(3), 408–414 (2015).
- Miller S . The acute and preventative treatment of episodic migraine. Ann. Indian Acad. Neurol.15(Suppl. 1), S33–S39 (2012).
- Bonafede M , McMorrowD , NoxonV , DesaiP , SapraS , SilbersteinS. Care among migraine patients in a commercially insured population. Neurol. Ther.9(1), 93–103 (2020).
- Hepp Z , DodickDW , VaronSF , GillardP , HansenRN , DevineEB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia Int. J. Headache35(6), 478–488 (2015).
- Kristoffersen ES , LundqvistC. Medication-overuse headache: epidemiology, diagnosis and treatment. Ther. Adv. Drug Saf.5(2), 87–99 (2014).
- Diener H-C , HolleD , SolbachK , GaulC. Medication-overuse headache: risk factors, pathophysiology and management. Nat. Rev. Neurol.12(10), 575–583 (2016).
- De Felice M , OssipovMH , WangRet al. Triptan-induced latent sensitization a possible basis for medication overuse headache. Ann. Neurol.67(3), 325–337 (2010).
- Nir R-R , YarnitskyD. Conditioned pain modulation. Curr. Opin. Support. Palliat. Care9(2), 131–137 (2015).
- Yarnitsky D , DodickDW , GrosbergBMet al. Remote electrical neuromodulation (REN) relieves acute migraine: a randomized, double-blind, placebo-controlled, multicenter trial. Headache59(8), 1240–1252 (2019).
- Grosberg B , RabanyL , LinTet al. Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: an open-label study. Pain Rep.6(4), e966 (2021).
- Nierenburg H , VieiraJR , LevNet al. Remote electrical neuromodulation for the acute treatment of migraine in patients with chronic migraine: an Open-Label Pilot study. Pain Ther.9(2), 531–543 (2020).
- Hershey AD , LinT , GruperYet al. Remote electrical neuromodulation for acute treatment of migraine in adolescents. Headache61(2), 310–317 (2021).
- Szumilas M . Explaining Odds Ratios. J. Can. Acad. Child Adolesc. Psychiatry19(3), 227–229 (2010).
- Rapoport AM , BonnerJH , LinTet al. Remote electrical neuromodulation (REN) in the acute treatment of migraine: a comparison with usual care and acute migraine medications. J. Headache Pain20(1), 83 (2019).
- Hershey AD , IrwinS , RabanyLet al. Comparison of remote electrical neuromodulation (REN) and standard-care medications for acute treatment of migraine in adolescents: a post-hoc analysis. Pain Med.23(4), 815–820 (2021).
- Cameron C , KellyS , HsiehS-Cet al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache55(Suppl. 4), 221–235 (2015).
- Marmura MJ , SilbersteinSD , SchwedtTJ. The acute treatment of migraine in adults: The American Headache Society evidence assessment of migraine pharmacotherapies. Headache55(1), 3–20 (2015).